Table 2. Open in new tab Univariate...

Characteristic

Remission [n = 57]

No remission [n = 36]

Odds ratio [95% CI]

Significance

Patient characteristics [at baseline]

Mean age [years]

31.88 ± 10.67

39.86 ± 10.57

0.93 [0.89–0.97]

0.001

Male gender [n][%]

38 [66.67]

20 [55.55]

1.6 [0.67–3.77]

0.280

Disease characteristics [at baseline]

Mean hamoglobin [g/dL]

9.87 ± 1.43

9.55 ± 1.09

1.22 [0.87–1.69]

0.244

Mean ESR [mm/h]

40.59 ± 8.67

40.14 ± 7.11

1.01 [0.96–1.06]

0.791

Mean serum albumin [g/L]

3.24 ± 0.31

3.20 ± 0.35

1.379 [0.38–4.97]

0.627

Mean CRP [mg/L]

15.31 ± 5.87

16.48 ± 6.43

0.969 [0.90–1.04]

0.369

Mean faecal calprotectin [µg/g]

354.18 ± 98.4

355.36 ± 87.09

1.0 [0.99–1.01]

0.953

Mean disease duration [years]

4.46 ± 3.80

6.24 ± 5.57

0.92 [0.84–1.01]

0.071

Disease extent E1^a [n] [%]

12 [21.05]

6 [16.66]

1.33 [0.45–3.93]

0.602

Disease extent E2^a [n] [%]

31 [54.38]

13 [36.11]

2.10 [0.89–4.96]

0.086

Disease extent E3^a [n] [%]

14 [24.56]

17 [47.22]

0.36 [0.14–0.88]

0.024

Moderate severity^b [n] [%]

48 [84.21]

23 [63.88]

3.01 [1.12–8.06]

0.025

Endoscopic Mayo score 2 [n] [%]

37 [64.91]

9 [25]

5.55 [2.18–14.06]

0.0003

Concomitant azathioprine [n] [%]

27 [47.36]

21 [58.33]

0.64 [0.27–1.49]

0.303

Concomitant corticosteroids at the time of enrolment [n] [%]

None

14 [24.56]

6 [16.66]

1.62 [0.56–4.71]

0.367

<20 mg prednisolone

5 [8.77]

4 [11.11]

0.76 [0.19–3.07]

0.710

≥20 mg prednisolone

38 [66.67]

26 [72.22]

0.76 [0.30–1.91]

0.573

Previous exposure to biologics [n] [%]

12 [21.05]

7 [26.92]

1.10 [0.38–3.13]

0.850

FMT variables

Retention time of faecal slurry [n] [%]

<1 h

5 [8.77]

3 [8.33]

1.06 [0.24–4.72]

0.941

1–4 h

27 [47.37]

16 [44.44]

1.13 [0.49–2.60]

0.783

≥4 h

25 [43.86]

17 [47.22]

0.87 [0.38–2.02]

0.751

Table 2.

Open in new tab

Univariate analysis of the factors determining response to faecal microbiota transplantation

Characteristic	Remission [n = 57]	No remission [n = 36]	Odds ratio [95% CI]	Significance
Patient characteristics [at baseline]
Mean age [years]	31.88 ± 10.67	39.86 ± 10.57	0.93 [0.89–0.97]	0.001
Male gender [n][%]	38 [66.67]	20 [55.55]	1.6 [0.67–3.77]	0.280
Disease characteristics [at baseline]
Mean hamoglobin [g/dL]	9.87 ± 1.43	9.55 ± 1.09	1.22 [0.87–1.69]	0.244
Mean ESR [mm/h]	40.59 ± 8.67	40.14 ± 7.11	1.01 [0.96–1.06]	0.791
Mean serum albumin [g/L]	3.24 ± 0.31	3.20 ± 0.35	1.379 [0.38–4.97]	0.627
Mean CRP [mg/L]	15.31 ± 5.87	16.48 ± 6.43	0.969 [0.90–1.04]	0.369
Mean faecal calprotectin [µg/g]	354.18 ± 98.4	355.36 ± 87.09	1.0 [0.99–1.01]	0.953
Mean disease duration [years]	4.46 ± 3.80	6.24 ± 5.57	0.92 [0.84–1.01]	0.071
Disease extent E1^a [n] [%]	12 [21.05]	6 [16.66]	1.33 [0.45–3.93]	0.602
Disease extent E2^a [n] [%]	31 [54.38]	13 [36.11]	2.10 [0.89–4.96]	0.086
Disease extent E3^a [n] [%]	14 [24.56]	17 [47.22]	0.36 [0.14–0.88]	0.024
Moderate severity^b [n] [%]	48 [84.21]	23 [63.88]	3.01 [1.12–8.06]	0.025
Endoscopic Mayo score 2 [n] [%]	37 [64.91]	9 [25]	5.55 [2.18–14.06]	0.0003
Concomitant azathioprine [n] [%]	27 [47.36]	21 [58.33]	0.64 [0.27–1.49]	0.303
Concomitant corticosteroids at the time of enrolment [n] [%]
None	14 [24.56]	6 [16.66]	1.62 [0.56–4.71]	0.367
<20 mg prednisolone	5 [8.77]	4 [11.11]	0.76 [0.19–3.07]	0.710
≥20 mg prednisolone	38 [66.67]	26 [72.22]	0.76 [0.30–1.91]	0.573
Previous exposure to biologics [n] [%]	12 [21.05]	7 [26.92]	1.10 [0.38–3.13]	0.850
FMT variables
Retention time of faecal slurry [n] [%]
<1 h	5 [8.77]	3 [8.33]	1.06 [0.24–4.72]	0.941
1–4 h	27 [47.37]	16 [44.44]	1.13 [0.49–2.60]	0.783
≥4 h	25 [43.86]	17 [47.22]	0.87 [0.38–2.02]	0.751

Characteristic	Remission [n = 57]	No remission [n = 36]	Odds ratio [95% CI]	Significance
Patient characteristics [at baseline]
Mean age [years]	31.88 ± 10.67	39.86 ± 10.57	0.93 [0.89–0.97]	0.001
Male gender [n][%]	38 [66.67]	20 [55.55]	1.6 [0.67–3.77]	0.280
Disease characteristics [at baseline]
Mean hamoglobin [g/dL]	9.87 ± 1.43	9.55 ± 1.09	1.22 [0.87–1.69]	0.244
Mean ESR [mm/h]	40.59 ± 8.67	40.14 ± 7.11	1.01 [0.96–1.06]	0.791
Mean serum albumin [g/L]	3.24 ± 0.31	3.20 ± 0.35	1.379 [0.38–4.97]	0.627
Mean CRP [mg/L]	15.31 ± 5.87	16.48 ± 6.43	0.969 [0.90–1.04]	0.369
Mean faecal calprotectin [µg/g]	354.18 ± 98.4	355.36 ± 87.09	1.0 [0.99–1.01]	0.953
Mean disease duration [years]	4.46 ± 3.80	6.24 ± 5.57	0.92 [0.84–1.01]	0.071
Disease extent E1^a [n] [%]	12 [21.05]	6 [16.66]	1.33 [0.45–3.93]	0.602
Disease extent E2^a [n] [%]	31 [54.38]	13 [36.11]	2.10 [0.89–4.96]	0.086
Disease extent E3^a [n] [%]	14 [24.56]	17 [47.22]	0.36 [0.14–0.88]	0.024
Moderate severity^b [n] [%]	48 [84.21]	23 [63.88]	3.01 [1.12–8.06]	0.025
Endoscopic Mayo score 2 [n] [%]	37 [64.91]	9 [25]	5.55 [2.18–14.06]	0.0003
Concomitant azathioprine [n] [%]	27 [47.36]	21 [58.33]	0.64 [0.27–1.49]	0.303
Concomitant corticosteroids at the time of enrolment [n] [%]
None	14 [24.56]	6 [16.66]	1.62 [0.56–4.71]	0.367
<20 mg prednisolone	5 [8.77]	4 [11.11]	0.76 [0.19–3.07]	0.710
≥20 mg prednisolone	38 [66.67]	26 [72.22]	0.76 [0.30–1.91]	0.573
Previous exposure to biologics [n] [%]	12 [21.05]	7 [26.92]	1.10 [0.38–3.13]	0.850
FMT variables
Retention time of faecal slurry [n] [%]
<1 h	5 [8.77]	3 [8.33]	1.06 [0.24–4.72]	0.941
1–4 h	27 [47.37]	16 [44.44]	1.13 [0.49–2.60]	0.783
≥4 h	25 [43.86]	17 [47.22]	0.87 [0.38–2.02]	0.751

ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.

^aE1: proctitis, E2: left-sided colitis, E3: pancolitis.

^bModerate severity: Mayo clinic score 6–9.

This Feature Is Available To Subscribers Only